Rupintrivir - Experimental Treatment for the Common Cold

 

Key Data:

Drug (Brand / Generic)
Rupintrivir (AG7088)
Company/Licensee
Agouron Pharmaceuticals (Pfizer subsidiary)
Therapy Class
Anti-viral agent
Product Description
Protease inhibitor
Current Indication
Treatment of colds due to rhinovirus infection
Market Sector
Anti-infectives
Development Status
Further development halted after failure in Phase II trials



Home
New On This Site
Products & Services
Company A-Z
Industry Projects
Features
White Papers
Jobs & Careers
Industry News
Gallery
Events & Exhibitions
Newsletter
Advertise With Us
About Us
Client Area


RSS What is RSS
For every phase of your drug development